The study adds to growing evidence that immunotherapy and chemoembolization prolong progression-free survival.

ASCO 2026 features promising research on hepatobiliary cancers, like new approaches to drugging the Wnt/beta-catenin pathway ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

Transarterial chemoembolization (TACE) is a type of treatment for liver cancer. It works by delivering chemotherapy drugs directly to the tumor and blocking its blood supply. Liver cancer occurs when ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Efficacy of PS-341 in combination with paclitaxel (PAC) and carboplatin (CBDCA) for the treatment of metastatic melanoma (MM): A phase II consortium study No significant financial relationships to ...

Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and D2 node dissection for gastric adenocarcinoma in INEN (Lima, Peru). Background: The global SPACE trial was conducted to evaluate ...